Introduction
Regulation of Notch signaling and repair of double-strand breaks (DSBs) is critical for maintaining tissue homeostasis and suppression of cancer. Notch signaling is important for the control of cellfate determination of mammary epithelial cell (MEC) progenitors, and its abnormal activation is associated with human and mouse breast tumorigenesis (1-3). Defective DSB signaling promotes genomic instability and increases the risk for various human neoplasms, including breast cancer (4) .
Notch signaling and DSB repair are highly regulated by posttranslational modifications including ubiquitylation (2, 5, 6) . The E3 ligase RNF8 ubiquitylates histone H1 at DSB flanking sites, triggering an orchestrated recruitment of signaling and repair proteins (e.g., the breast cancer susceptibility protein BRCA1) to facilitate the repair of the break sites (7) (8) (9) (10) (11) (12) (13) . Despite impaired DSB repair signaling in the absence of RNF8, and the reported RNF8 function in the activation of TWIST and cancer metastasis (14) , whether deficiency of RNF8 promotes breast cancer initiation and development has yet to be examined. Here, we aimed to address the effect of Rnf8 mutation on mammary tumorigenesis. Notably, we also uncovered novel functions of RNF8 in the regulation of Notch signaling and cell-fate determination of MECs. Given the importance of DSB repair and Notch signaling in breast cancer, identification of mechanisms that coregulate these pathways will not only reveal novel key cancer drivers, but also can potentially provide novel, more effective, and precise therapeutic strategies.
Results

RNF8 deficiency promotes mouse mammary tumorigenesis.
To examine whether RNF8 deficiency fosters mammary tumorigenesis, we first examined mammary tissues of Rnf8 -/-female mice. While Rnf8 -/-females frequently developed hyperplastic lesions in mammary tissues at 13 months of age (60%; 12 of 20), no hyperplasia was observed in WT littermates (n = 19; Supplemental Figure 1, A and B; supplemental material available online with this article; https://doi.org/10.1172/JCI120401DS1). Next, monitoring the cohorts of Rnf8 -/-females and WT controls for over 600 days, we observed that in addition to thymomas and/or lymphomas, 18% of Rnf8 -/-females (6 of 33) also developed mammary adenocarcinomas ( Figure 1, A and B) .
Human TP53, and its mouse ortholog TRP53, are tumor suppressors important for the DNA damage response (DDR) (15, 16) .
Examination of Rnf8
-/-mammary glands indicated upregulated expression of TRP53 and its transcriptional targets P21 and BAX, suggesting abnormally activated DDR in the absence of RNF8 (Supplemental Figure 1C) . Based on the frequent mutations of TP53 in human breast cancer (17) , we sought to examine the effect of inactivation of TRP53 in mammary tumorigenesis associated
The E3 ubiquitin ligase RNF8 plays critical roles in maintaining genomic stability by promoting the repair of DNA doublestrand breaks (DSBs) through ubiquitin signaling. Abnormal activation of Notch signaling and defective repair of DSBs promote breast cancer risk. Here, we found that low expression of the full-length RNF8 correlated with poor prognosis for breast cancer patients. Our data revealed that in addition to its role in the repair of DSBs, RNF8 regulated Notch1 signaling and cell-fate determination of mammary luminal progenitors. Mechanistically, RNF8 acted as a negative regulator of Notch signaling by ubiquitylating the active NOTCH1 protein (N1ICD), leading to its degradation. Consistent with abnormal activation of Notch signaling and impaired repair of DSBs in Rnf8-mutant mammary epithelial cells, we observed increased risk of mammary tumorigenesis in mouse models for RNF8 deficiency. Notably, deficiency of RNF8 sensitized breast cancer cells to combination of pharmacological inhibitors of Notch signaling and poly(ADP-ribose) polymerase (PARP), suggesting implications for treatment of breast cancer associated with impaired RNF8 expression or function.
In contrast, the other RNF8 isoforms (201, 204, and 208 ) lack the FHA domain, the RING-finger domain, or both and therefore are predicted to be nonfunctional ( Figure 2A ). KM Plotter analysis of breast cancer patients was performed using the median expression level as the cutoff. Since the 203160_s_at probe set recognizes RNF8 transcripts lacking functional domains (Figure 2A ), these analyses indicated a modest association between high RNF8 expression and reduced relapse-free survival of breast cancer patients (Supplemental Figure 2A ; hazard ratio = 1.15 [1.03-1.28], log-rank P = 0.013). However, the same analysis using the functionally relevant RNF8 probe set (203161_s_at), specific to the full transcript encoding the functional RNF8, revealed that low RNF8 expression significantly associates with poorer outcome ( Figure 2B ; hazard ratio = 0.82 [0.74-0.92], log-rank P = 4 × 10 -04
). The strongest associations using RNF8 203161_s_at were observed for luminal B and basal-like breast cancer subtypes ( Figure 2 , C and D). The HER2 + subtype showed an effect in the same direction, although with lower significance due to the substantially smaller sample size in this setting ( Figure 2E ).
RNF8 deficiency promotes genomic instability in MECs and tumors.
Given the established role of genomic instability in driving cancer (23) , we examined the effect of RNF8 deficiency on DSB signaling, repair, and genomic integrity in MECs. Examination of γH2AX foci, a marker for DSBs (24) , indicated elevated levels of spontaneous and γ-irradiation-induced (IRinduced) DSBs in Rnf8 -/-MECs compared with WT controls (Figure 3, A WT also restored the ability of these tumor cells to recruit homologous recombination (HR) and nonhomologous end joining (NHEJ) repair factors BRCA1, RAD51, and 53BP1 to DSB sites ( Figure 3 , D-F). Consistent with these data, complementation of RNF8-deficient tumor cells with RNF8 significantly increased their efficiency of HR-and NHEJ-mediated DSB repair ( Figure 3 , G and H). Collectively these data underscore the importance of RNF8 for maintaining genomic stability in mammary cancer cells and tumors. Aberrant expansion of the mammary luminal progenitors in the absence of RNF8. Deregulated lineage commitment of MECs has been shown to be associated with increased breast cancer risk (1, 25) . Therefore, we also investigated the role of RNF8 in mammary gland development and its link to tumorigenesis. First, analysis of Rnf8 expression in mammary cell subpopulations indicated a significantly lower level in luminal progenitors compared with luminal differentiated and basal cells (Supplemental Figure 3A) . Next, mammary epithelial subpopulations of 10-to 12-week-old, tumorfree, Rnf8 -/-females and WT littermates were examined for potential differences. Notably, studied females were in estrus to alleviate hormonal effects on homeostasis of MECs (26, 27 ) also displayed elevated risk for developing mammary tumors, and these malignant lesions showed loss of heterozygosity for Trp53 ( Figure 1A and Supplemental Figure 1E Figure 1F) , and exhibited metastasis to other organs (e.g., lung, lymph nodes, and brain) as confirmed by pan-CK staining (Supplemental Figure 1F) . Moreover, Figure 1G) .
Next, we sought to examine the effect of complementation of Rnf8-deficient mammary tumor cells with Rnf8
WT on their in vivo growth capacity. We observed that relative to empty-vector controls, RNF8-reconstituted Rnf8 -/-Trp53 Δ/Δ tumor cells showed reduced growth when engrafted in inguinal fat pads of NOD scid gamma (NSG) mice as measured by tumor volume and mass (Figure 1 , C-E, and Supplemental Figure 1H ). Examination of the corresponding tumors revealed that RNF8
WT reconstitution significantly restrained cancer cell proliferation as assessed with Ki67 staining (Supplemental Figure 1, I and J). Collectively, these data highlight the importance of RNF8 expression, and its collaboration with TRP53 function, in suppressing mammary tumorigenesis.
Low expression of the full-length RNF8 correlates with poor prognosis of breast cancer patients. To examine the clinical relevance of RNF8 expression levels in human breast cancer subtypes, we used the Kaplan-Meier Plotter (KM Plotter) tool to analyze an integrated data set including 5,143 breast cancer cases of which 3,955 had relapsefree survival information (19) . Two Affymetrix microarray probes for RNF8 are included in the application (Figure 2A ). Disparity of results between microarray probes supposedly mapping on a single gene target has been previously recognized (e.g., BRCA1 and MYC) (20) (21) (22) . Therefore, we first examined curated Ensembl annotations and observed that the human RNF8 locus includes at least 4 isoforms (Figure 2A) . Examination of the 2 Affymetrix microarray probes for RNF8 indicated that they display different specificity toward these isoforms. While 203160_s_at recognizes all 4 isoforms, 203161_s_at only recognizes the transcript (RNF8-202) that encodes for the complete functional protein (according to UniProt, O76064_1), including its forkhead-associated (FHA) and RING-finger domains (Figure 2A) , both required for RNF8 function in DSB repair (7) (8) (9) (10) Figure  5C ). Consistent with these data, Rnf8 -/-Trp53 Δ/Δ mammary tumor cells displayed elevated expression of N1ICD and its targets (HES1 and CCND1), and the activation of Notch1 signaling was restrained following RNF8
WT reconstitution ( Figure 5D and Supplemental Figure  1H ). In addition, expression of NOTCH targets was higher in mockreconstituted Rnf8 -/-Trp53 Δ/Δ mammary tumor cells engrafted into NSG mice, compared with the corresponding RNF8 WT -reconstituted controls ( Figure 5E ). Moreover, a reporter for Notch signaling activity (10xCBF1-Luc) (33) confirmed RNF8-mediated negative regulation of NOTCH transcriptional activity in RNF8
Trp53
Δ/Δ cells ( Figure 5F ). To further investigate the functional relevance of RNF8 to the regulation of Notch signaling, we compared RNA sequencing data obtained from Rnf8 -/-Trp53 Δ/Δ mammary tumor cells and RNF8 WT -reconstituted controls. Transcriptional upregulation of several NOTCH-target genes and components of the pathway were observed in RNF8-deficient cells ( Figure 5G ). Downregulation of a few Notch pathway elements was also observed (e.g., Numbl and Maml2; Figure 5G ), perhaps reflecting the complex regulation of this signaling pathway and that, in addition to positive feedback, activation of Notch signaling also promotes negative feedback regulation (5). Quantitative expression analyses performed on 3 different Rnf8 -/-Trp53 Δ/Δ mammary tumors reconstituted with either mock or RNF8
WT confirmed the changes in expression of NOTCH-target genes associated with RNF8 deficiency ( Figure 5H ). These data reveal novel functions of RNF8 as a negative regulator of Notch signaling in mouse mammary luminal progenitors and tumors.
RNF8 mediates negative regulation of Notch signaling in human breast cancer. To extend our studies of the effect of RNF8 on Notch signaling to relevant human breast cancer cells, we first performed quantitative expression analysis in RNF8-depleted breast cancer cell lines. Our data indicate a significant increase in the expression of NOTCH targets (HES1, HES2, HEY1, HEY2, and CCND1) in RNF8-depleted breast cancer cell lines compared with controls (Figure 6A and Supplemental Figure 4B ). Consistent with these findings, overexpression of ectopic RNF8
WT in the breast cancer cell line MDA-MB-231 significantly reduced the protein level of N1ICD ( Figure 6B ), while CRISPR/Cas9-mediated knockout of RNF8 in MDA-MB-231 and MCF7 cells led to increased protein expression of N1ICD and its downstream target HES1 ( Figure 6C and Supplemental Figure  4C ). Further supporting the link between RNF8 and Notch signaling in human breast cancer cells, analysis of data from The Cancer Genome Atlas (TCGA) revealed significant negative correlations between the expression of RNF8 and several NOTCH-target genes (HES1, HES2, HES5, HEY1, and CCND1), whereas positive correlations were found with HDAC2, HIF1A, and NUMBL ( Figure 6D ).
To further assess the RNF8-NOTCH link and examine whether it is influenced by TP53 mutations, the TCGA data were analyzed Next, we examined the clonal growth potential of Rnf8
MECs using a 3D colony-forming cell (CFC) assay (28) . The number of CFCs was found to be double and the colonies were larger in size in Rnf8 -/-relative to WT cell controls ( Figure 4G and Supplemental Figure 3D ). Moreover, Rnf8 -/-mammary glands exhibited a 4-fold increase in the number of proliferating cells as indicated by Ki67 positivity ( Figure 4H ). Taken together, these data indicate that RNF8 deficiency promotes aberrant expansion of luminal progenitor cells in the mouse mammary epithelium.
Following on the previous observations and considering that TRP53 deficiency increased the risk of breast cancer in Rnf8 Figure 3 , F and G). Whole-mount staining of the axillary mammary glands from these 6.5-month-old females showed no sign of hyperplasia (Supplemental Figure 3H ), precluding contribution of hyperplasia to the observed aberrant expansion of luminal progenitors in the absence of RNF8. These data unveil a novel function for RNF8 in the regulation of luminal lineage cell fate.
RNF8 negatively regulates Notch signaling in murine mammary luminal progenitors and tumors. On the basis of the aberrant expansion of luminal progenitors in Rnf8-mutant females, we hypothesized that RNF8 regulates signaling pathways required for epithelial cell-fate determination. Therefore, we examined mammary cell subpopulations sorted from Rnf8 -/-and WT females for expression of genes whose alterations are known to promote luminal expansion. Notably, the Notch signaling that plays important roles in the luminal cell-fate commitment (1, 29, 30) was found to be activated in Rnf8 -/-luminal progenitors as indicated by the significantly increased expression of the Notch-target genes Hes1, Hey1, Slug, and Ccnd1 ( Figure 5A ). The expression level of the proliferation marker Ccnd2 was also found to be increased in Rnf8 -/-luminal progenitors, while expression of p18 INK4c and FoxM1, factors involved in regulating mammary luminal cell fate (31, 32) , remained unaffected by RNF8 deficiency ( Figure 5A ). Next, given that interaction of NOTCH1 receptor with its ligands triggers its proteolytic cleavage and the release of its activated intracellular domain (N1ICD) (5), the effect of RNF8 deficiency on N1ICD expression level was analyzed in MECs.
Rnf8
-/-and Rnf8 -/-Trp53 Δ/Δ primary MECs were found to display elevated protein levels of N1ICD and its canonical target HES1 ( Figure 5B and Supplemental Figure 4A) for pathway associations using RNF8 coexpression ranks from all tumors or from those with somatic TP53 mutations. RNF8 expression was found to be negatively correlated with the Pathway Interaction Database (PID) NOTCH set in both settings (Supplemental Figure 4D ). These data are consistent with the observed activation of Notch signaling in both RNF8-deficient MCF7 (TP53-WT) and MDA-MB-231 (TP53-mutant) breast cancer cell lines ( Figure  6C and Supplemental Figure 4C ). Taken together, these results indicate that, as in murine mammary luminal progenitors and mammary tumors, RNF8 negatively regulates Notch signaling in human breast cancer. RNF8 ubiquitylates N1ICD to control its turnover. To understand the molecular mechanisms underlying the observed negative regulation of Notch signaling, we first examined whether RNF8 interacts with components of the corresponding pathway. N1ICD was detected in FLAG-tagged RNF8 immunoprecipitates from Rnf8
Trp53
Δ/Δ mammary tumors reconstituted with RNF8-FLAG ( Figure  7A ). Notably, no interaction was detected between RNF8 and RBPJ, a Notch transcriptional effector (2), and deficiency of RNF8 had no effect on RBPJ expression (Supplemental Figure 5A) .
Ubiquitylation of N1ICD is critical for the regulation of its turnover (2) . Examination of the expression of FBW7, an E3 ligase important for N1ICD ubiquitylation and degradation (2, 5), indicated that it was unaffected by RNF8 deficiency (Supplemental Figure 5B) . Next, we sought to determine whether RNF8 ubiquitylates N1ICD. First, we performed an in vivo ubiquitylation assay and examined the effect of RNF8 deficiency on the ubiquitylation of endogenous N1ICD. Immunoprecipitated N1ICD from RNF8-deficient mammary tumor cells reconstituted with RNF8-FLAG, and left untreated or treated with the proteasome inhibitor MG132, migrated on SDS-PAGE gels as higher-molecular weight smears that were reactive to anti-ubiquitin (Ub) ( Figure 7B ). In contrast, these N1ICD Ub smears were greatly reduced in mockreconstituted RNF8-deficient mammary tumor cells ( Figure 7B ). Next, we examined the effect of RNF8 on the ubiquitylation of the endogenous human N1ICD and observed that deficiency of RNF8 in MDA-MB-231 cells remarkably decreased the ubiquitylation level of nuclear N1ICD ( Figure 7C ).
Ubiquitylation assays performed in HEK293T cells further supported RNF8-mediated polyubiquitylation of N1ICD, as co expression of exogenous RNF8 and Ub in these cells produced robust Ub smears of N1ICD compared with controls ( Supplemental Figure 5C) . Furthermore, examination of RNF8-catalyzed Ub linkages for N1ICD polyubiquitylation indicated that RNF8 mediates both K63 and K48 ubiquitylation of N1ICD (Supplemental Figure  5C ). Finally, in vitro ubiquitylation assays using recombinant proteins (RNF8, N1ICD, E1, E2, and Ub) confirmed that N1ICD is a novel and direct ubiquitylation substrate for RNF8 ( Figure 7D ).
The importance of ubiquitylation in protein turnover (34, 35) and the elevated N1ICD levels in RNF8-deficient mammary cells and tumors prompted us to perform cycloheximide chase experiments and examine the regulatory role of RNF8 on N1ICD. A strong reduction of the half-life of N1ICD was observed in RNF8-deficient mammary tumors upon their complementation with RNF8
WT ( Figure 7E ). RNF8 RING-finger and FHA domains are required for its function in DSB signaling (7) (8) (9) (10) . Therefore, we examined the contribution of these domains to RNF8-mediated negative regulation of Notch signaling. Similarly to its inability to stimulate DSB signaling and repair (8), a catalytic dead form of RNF8 that carries C406S substitution in the RING-finger domain (RNF8 C406S ) was defective in mediating N1ICD ubiquitylation and degradation (Figure 7 , F and G). However, in contrast to the inability of the FHA mutant RNF8
R42A to activate the repair cascade of DSBs (8, 9) , this RNF8 mutant form effectively mediated N1ICD degradation (Figure 7G ). These findings highlight the importance of the E3 ligase activity of RNF8 for N1ICD ubiquitylation and turnover, and indicate that RNF8 negatively regulates Notch signaling in a manner independent of its recruitment to DSB sites.
Combined pharmacological inhibition of Notch signaling and PARP function promotes killing of RNF8-deficient breast tumors.
Based on the importance of RNF8 in Notch signaling and DSB repair, we examined whether impaired RNF8 function in breast cancer could be exploited therapeutically. First, exposure to different γ-secretase inhibitors (GSIs; RO4929097, YO-01027, and LY411575), which block Notch signaling, led to a significant growth impairment of Rnf8 WT -reconstituted controls. *P < 0.05, **P < 0.01, ***P < 0.001. H: All P values were less than 0.05. jci.org Volume 128 Number 10 October 2018
naling, and similarly to mouse cell models, RNF8-deficient MCF7 and MDA-MB-231 cells displayed increased sensitivity to GSI and PARPi (Figure 8 , E-G). Importantly, both human cell models deficient for RNF8 (Figure 8 
, E-G), as well as Rnf8 -/-Trp53
Δ/Δ mouse mammary tumor cells (Figure 8 , H and I), displayed higher sensitivity to the combination of GSI and PARPi compared with the respective controls. In summary, evidence from human and mouse breast cancer models highlights that combination of inhibitors of Notch signaling and PARP provides a precise therapeutic strategy for breast tumors with defective RNF8 function.
Discussion
Notch signaling and DSB signaling are fundamental cellular processes, and their regulation is critical for minimizing breast cancer risks (2, 3, 23). Although these pathways are highly regulated, the lethality of cancer cells defective for HR-mediated repair (36) . Considering the inherent defects of DSB signaling and HR-mediated repair associated with RNF8 deficiency (Figure 3) , we examined the response of Rnf8 -/-Trp53 Δ/Δ mammary tumor cells, complemented with empty vector or RNF8 WT , to IR and PARPi (KU0058948 and olaparib). In accordance with their impaired DSB repair and defective homologous recombination pathway, RNF8-deficient mammary tumor cells were highly sensitive to both IR and PARPi compared with their control counterparts ( Figure 8, C and D) .
Next, the above therapeutic opportunity was assessed in human breast cancer cells. Examination of RNF8-deficient MDA-MB-231 and MCF7 breast cancer cells showed impaired DSB repair as indicated by accumulation of unresolved γH2AX foci 24 hours after IR (Supplemental Figure 6 , C-E). Consistent with their impaired repair of DSBs and increased activation of Notch1 sig- or their combination as indicated. B-D, F , G, and I: n = 3; mean ± SEM, normalized to DMSO-treated controls except for C, in which normalization was to nonirradiated controls. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, 2-way ANOVA followed by Tukey's test. jci.org Volume 128 Number 10 October 2018 dispensable for RNF8-mediated downregulation of Notch signaling. Therefore, despite coregulation of Notch signaling and DSB repair, recruitment of RNF8 to chromatin at DSBs, or its possible binding to phosphorylated proteins through its FHA domain, is not required for ubiquitylation of N1ICD. Therefore, the initial mechanisms by which RNF8 engages its regulation of Notch1 signaling and DSB repair cascade appear to be different. Combination therapy offers the advantage of targeting different molecular processes to enhance tumor cell death and reduce the risk of cancer recurrence. The simultaneous alteration of Notch signaling and DSB repair associated with defective RNF8 expression in breast cancer provides a unique therapeutic opportunity using specific inhibitors of Notch and PARP. Indeed, we observed increased sensitivity of mouse and human breast cancer cells deficient for RNF8 to individual treatment with GSI or PARPi. Notably, this sensitivity of RNF8-deficient breast cancer cells was further increased in response to combination of pharmacological inhibitors of Notch signaling and PARP.
In summary, our data uncover an unanticipated role for RNF8 in the regulation of cell-fate determination of mammary luminal progenitors and demonstrate a novel function for RNF8 in the regulation of Notch1 signaling through the control of N1ICD turnover. We also provide evidence that RNF8 deficiency increases the risk of mammary tumorigenesis. Thus, while RNF8 is an integral component of DSB signaling and, as such, its deficiency or loss of function can potentially contribute to increased breast cancer risk, we propose that the novel role of RNF8 in fine-tuning Notch1 signaling is not only important for cell-fate determination of luminal progenitors, but also contributes to protection from breast cancer development (Figure 9 ). The high efficacy of combination treatment of RNF8-deficient breast tumors with GSI and PARPi suggests that such combination may have therapeutic benefit for patients with defective expression or function of RNF8. Elucidation of the mechanisms that modulate RNF8's negative regulation of Notch1 signaling and its impact on the fate and transformation of MECs sheds new light on the mechanisms of breast cancer development and uncovers a novel avenue for targeted therapy.
Methods
Mice. Rnf8
-/-mice (AS0574 strain) were previously reported (11) . common 5′-TGGATGGTGGTATACTCAGAGC-3′), and Cre (forward 5′-CCATCTGCCACCAGCCAG-3′; reverse 5′-TCGCCATCTTCCAG-CAGG-3′). All mice were housed in a pathogen-free mouse facility at the Princess Margaret Cancer Centre. Ten-to 12-week-old female mice were used for experiments, unless indicated otherwise in the figure legends. To rule out the effect of hormonal changes on MECs mechanisms that may mediate their coregulation remain poorly understood. This work reveals that RNF8 mediates this coregulation of Notch and DSB signaling in the mammary epithelium and, if perturbed, promotes breast cancer ( Figure 9 ). Notch signaling is essential for luminal cell-fate determination in the mammary epithelium (1, 29). Constitutive activation of Notch signaling in mammary luminal progenitors promotes the expansion of these progenitors and increases the risk for their malignant transformation (1, 29, 30) . In this study, we demonstrate that RNF8 is a potent negative regulator of Notch signaling and its deficiency in MECs causes sustained activation of this signaling, likely contributing to the aberrant expansion of mammary luminal progenitors. Our study reveals that RNF8 negatively regulates the Notch1 signaling pathway through its ubiquitylation of N1ICD, and its subsequent targeting for degradation. By restraining intracellular levels of N1ICD, RNF8 restrains transcriptional activity of NOTCH-target genes to promote tissue homeostasis. Consistent with the elevated levels of N1ICD and activation of Notch signaling in mammary epithelium of Rnf8-mutant female mice, human breast cancer cell lines deficient for RNF8 also displayed elevated levels of N1ICD and Notch signaling. Gene expression profile analyses using TCGA breast cancer data support the link between low RNF8 expression and abnormal Notch signaling.
The existence of several RNF8 isoforms prompted us to examine whether a correlation exists between breast cancer relapse-free survival and the expression level of the full-length isoform that encodes for functional RNF8. These analyses revealed that low expression of the full-length RNF8 isoform that contains both its FHA and RING-finger domains correlates with poor prognosis for breast cancer patients. These data suggest a prognostic role for the integral function of RNF8 in breast cancer. This link may be independent of an impact on breast cancer initiation; however, our results examining female mice carrying mutation of Rnf8 indicate that loss of RNF8 increases the risk of mammary tumorigenesis. Nonetheless, studies in different cancer settings may be warranted to further decipher the proposed dual impact of RNF8 on breast cancer.
Given the novel role of RNF8 as a negative regulator of Notch signaling, we hypothesized that when RNF8 is absent or nonfunctional, sustained Notch1 signaling drives aberrant proliferation of luminal progenitor cells. This aberrant proliferation, in conjunction with increased genomic instability, in the absence of RNF8 results in spontaneous mammary tumorigenesis. Consistent with elevated levels of DSBs and TRP53 activation in RNF8-deficient MECs, the risk of spontaneous mammary tumorigenesis in Rnf8 -/-females was further increased in the presence of homozygous or heterozygous Trp53 mutations in mammary epithelium. Our observation that tumors isolated from Rnf8 -/-Trp53 Δ/WT mice often displayed a loss of heterozygosity for Trp53 suggests that activated TRP53 plays a critical role in the suppression of RNF8-associated mammary tumorigenesis.
The RING-finger domain of RNF8 is critical for its E3 ligase function and for the positive regulation of DSB signaling cascade (7-10). Our study demonstrates that the RNF8 RING-finger domain is also essential to mediate negative regulation of Notch1 signaling. In contrast, the phosphothreonine-binding FHA domain of RNF8 responsible for recruitment of RNF8 to DSB sites (7-10) is jci.org Volume 128 Number 10 October 2018
opaque 96-well tissue culture plates (Greiner CellStar). Luciferase activities of the transfected cells were measured using the Dual Glo Luciferase assay kit (Promega) with firefly luciferase-based reporter gene activity normalized to the Renilla luciferase internal control reporter activity. Background autoluminescence from nontransfected cells was subtracted from the autoluminescence of the transfected cells. Transfection and virus transduction. HEK293T cells (ATCC) and the human breast cancer cell line MDA-MB-231 (ATCC) were transfected using PolyJet DNA in vitro transfection reagent (SignaGen Laboratories). Mouse mammary tumors were processed into single-cell suspensions following the same procedure for mammary gland singlecell suspension described above. Then, mammary tumor cells were analyzed by flow cytometry for Lin -expression of CD49f, CD24, and CD61, and were cultured in vitro into stable cell lines and validated by Western blot, PCR, and Southern blot for their respective mutations. All tumor cells were cultured in DMEM supplemented with 10% FBS, 5 × 10 -5 M 2-ME, 100 U/ml penicillin, and 100 μg/ml streptomycin (complete DMEM), and were maintained in a humidified atmosphere at 37°C and 5% CO 2 . To complement Rnf8 -/-Trp53 Δ/Δ mammary tumor cell lines with WT and mutant forms of RNF8, cDNA for mouse Rnf8 (WT, C406S, and R42A) was subcloned into MSCV-FLAG. Rnf8 retroviral constructs and empty MSCV-FLAG were transfected to Phoenix cells, and virus supernatants were collected 48 and 72 hours after transfection. Three independent mammary tumor cell lines were transduced with the harvested retroviral supernatants in the presence of Polybrene, and selected for puromycin resistance. Human breast cancer cell lines MDA-MB-231, MDA-MB-468, and T47D (ATCC) were transduced with PLKO-puro lentiviruses encoding shRNAs targeting human RNF8 (shRNA#1: TRCN0000003438, 5′-TGGAG-CAACTAGAGAAGACTT-3′; and shRNA#2: TRCN0000003441, 5′-CCAAAGAATGACCAAATGATA-3′). As control, cells were transduced with lentiviral particles carrying the empty pLKO.1-puro vector (Addgene, 8453). The expression of RNF8 was examined by Western (26, 27) , all experimental females were followed to determine their phases of estrus cycle for at least 4 continuous days. Females at the estrus cycle were used for all experiments. Survival cohorts of female mice were monitored for mammary tumor onset by palpation as well as signs of other tumors twice a week for over 600 days. Power analysis was performed to determine the minimum number of animals needed to have a statistical power of 80% for comparing Rnf8 Histological analysis and immunohistochemistry. Paraffin sections of mammary glands and mammary tumors were stained with H&E for histological analysis as previously described (11) . For immunohistochemistry, tissues and tumor sections were prepared according to standard protocols (11) . Antibodies used were anti-CK18 (10R-10302; Fitzgerald), anti-CK14 (PRB-155P; Covance), anti-Ki67 (NB500-170; Novus Biologicals), and anti-N1ICD (4147, Val1744 [D3B8]; Cell Signaling Technology). The investigators were blinded during the scoring of Ki67 + cells.
Immunofluorescence. Staining for subnuclear foci formation was performed as previously described (11) . MECs from females at estrus phase were purified by negative depletion using magnetic beads (Dynabeads; Invitrogen). FACS analysis indicated that the purity of the isolated MECs was greater than 97%. Immunofluorescence staining for subnuclear foci was also performed on RNF8-deficient mammary tumors and human breast cancer cell lines MDA-MB-231 and MCF7. Primary antibodies used for immunofluorescence staining were anti-γH2AX (07-164, Millipore; 05-636 JBW301, Millipore), anti-53BP1 (A300-272; Bethyl), anti-RAD51 (sc-8349, clone H-92; Santa Cruz Biotechnology), and anti-BRCA1 (39) (homemade, raised against aa 831-845 of murine BRCA1). Anti-rabbit or anti-mouse IgG conjugated with Alexa Fluor 488 or 594 (Invitrogen, catalog A11008, A11037, A11059, A11032) was used for secondary staining. Subsequently, slides were counterstained with DAPI (Invitrogen) and mounted with Mowiol (Sigma-Aldrich). Images were taken using a fluorescence microscope (Leica) under ×100 magnifications. ImageJ software (NIH) was used to process the raw data. The investigators were blinded during the scoring of foci-positive cells.
Clonogenic survival assay. Exponentially growing mouse mammary and human breast tumor cells were seeded at 200 cells per 6-cm dish in complete DMEM. Tumor cells were either left untreated, cultured in the presence of 0.1-5 μM of PARP inhibitor (KU0058948, Axon Medchem; or olaparib, Selleckchem), or subjected to γ-irradiation (2-8 Gy). For Notch inhibitor treatment, mammary tumor cells were either left untreated or treated with γ-secretase inhibitors (RO4929097, 1-10 μM; LY411575, 5 μM; YO-01027, 5 μM; Selleckchem). Olaparib (2 μM) and RO4929097 (10 μM) were used for combination treatments.
blotting. Human breast cancer cell lines MDA-MB-231 and MCF7 (ATCC) were also transduced with lentiCRISPR v2 (Addgene, 52961) lentiviruses encoding short-guide RNAs (sgRNAs) targeting human RNF8 (sgRNF8.1: 5′-CGGGGTCGAGTAGGCGATGG-3′; sgRNF8.2: 5′-CCATCGCCTACTCGACCCCG-3′) or a control lentiCRISPR v2 vector loaded with a sgRNA targeting a noncoding region of chromosome 10 (sgCh10: 5′-CAATACACCCATAGTTGAGC-3′). All cell lines were tested to be mycoplasma-free.
DSB repair assays. To determine HR and NHEJ efficiency, HR and NHEJ reporter constructs (38) were linearized with the I-SceI restriction enzyme and transfected to mammary tumor cell lines using GenJet in vitro DNA transfection kit (SignaGen Laboratories). RFP construct was cotransfected as internal control. Transfected cells were examined 48 hours later by flow cytometry for their expression of eGFP and RFP. Repair efficiencies of HR and NHEJ were expressed as eGFP + /RFP + ratios.
Flow cytometry analysis and sorting of MECs. Mammary glands from female mice at estrus phase were processed into mouse EpiCult-B medium supplemented with 3% FBS (Wisent), 750 U/ml collagenase, and 250 U/ml hyaluronidase, and incubated at 37°C for 2.5 hours. Subsequently, mammary organoids were subjected to red blood cell lysis in NH 4 Cl, followed by further dissociation in 0.25% trypsin for 2 minutes, and then in a mixture of 5 mg/ml dispase and 0.1 mg/ml DNase I for 2 minutes. After filtering through a 40-μm mesh, mammary singlecell suspensions were obtained. All the reagents described above were from STEMCELL Technologies, and all antibodies described below were from Thermo Fisher Scientific unless otherwise indicated. Mammary cell suspensions were blocked with Fc receptor antibody, followed by incubation with biotinylated anti-CD31 (14-0311), anti-CD45 (13-0451; clone 30-F11), and anti-TER119 (13-5921). CD45 + immune cells, TER119
+ red blood cells, and CD31 + endothelial cells were further conjugated with streptavidin-PE-Cy7 (25-4317) and were excluded using flow cytometry. Propidium iodide (Sigma-Aldrich) was used to stain dead cells, which were excluded from analysis. MEC subpopulations were identified using anti-CD49f-FITC (11-0495; clone GoH3), anti-CD24-PE (12-0242; clone M1/69), anti-CD29-FITC (11-0291; clone ebioHMb1-1), and anti-CD61-APC (MCD6105; Invitrogen) using a FACSCalibur (BD Biosciences) or Canto (BD Biosciences) and analyzed using FlowJo software (Tree Star Inc.). Cell sorting of mammary epithelial subpopulations was performed on a FACSAria (BD Biosciences), and the purity of sorted populations was routinely greater than 97%. Whole-mount staining. Mammary glands from females were mounted on glass slides and fixed with Carnoy's formula 2 fixative (10% glacial acetic acid, 30% chloroform, and 60% absolute ethanol) for 12 hours. Fixed mammary glands were processed through a hydration series using descending concentrations of ethanol (70%, 50%, and 20%; 15 minutes each) and distilled water for 10 minutes, followed by staining in a carmine-alum mix (0.2% carmine [SigmaAldrich] and 0.5% aluminum potassium sulfate [Sigma-Aldrich]) for 16 hours. Subsequently, the stained mammary glands were de hydrated through ascending concentrations of ethanol (25%, 50%, 70%, and 100%; 15 minutes each) and cleared in xylene overnight, and then the stained mammary glands were mounted with Permount medium (Fisher Scientific).
3D Matrigel mammary colony-forming assay. Mammary singlecell suspensions were prepared as described above from inguinal jci.org Volume 128 Number 10 October 2018 masked for low-complexity or low-quality sequence, and subsequently mapped to the mouse genome (build mm10, GRCm38) using STAR (version 2.4.0f1) (40) . The SAM/BAM files were further processed using SAMtools (version 0.1.18) (41), and read count quantitation was obtained using BEDTools multicov (version 2.25.0) (42) . Normalization of read counts and differential expression analysis between genotypes were carried out using the DESeq2 R package in Bioconductor (release 2.13). The Notch signaling pathway annotation was obtained from WikiPathways (43) .
In vivo ubiquitylation assay. Rnf8 -/-mammary tumor cells complemented with empty FLAG vector or RNF8-FLAG were either left untreated or treated with the proteasome inhibitor MG132 (20 μM; Selleckchem) for 6 hours, and ubiquitylation levels of N1ICD were examined as previously described (44 Forty-eight hours later, cell lysates were prepared, precleared with Protein A-Sepharose beads (Life Technologies), and subjected to immunoprecipitation using anti-N1ICD (Cell Signaling Technology). Subsequently, the beads were washed, and proteins released from the beads by boiling in 2× SDS-PAGE sample buffer. Immunoblot analysis was performed using the indicated antibodies.
In vitro ubiquitylation assay. Recombinant RNF8 (45) was a gift from T.K. Sixma (Division of Biochemistry and Cancer Genomics Centre, Netherlands Cancer Institute, Amsterdam, the Netherlands). UBE1, Ubc13, and Ub recombinant proteins were gifts from C. Arrowsmith (Princess Margaret Cancer Centre, University Health Network and Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada). Recombinant N1ICD (2 μg; Addgene, 47612), recombinant RNF8 (1 μg), UBE1 (0.1 μg; E1), Ubc13 (0.2 μg; E2), Ub (5 μg), and ATP (5 mM) were mixed, and the reactions were incubated at 30°C for 2 hours in buffer containing 50 mM Tris/HCl (pH 7.5), 5 mM MgCl 2 , and 1 mM DTT and examined by immunoblot as previously reported (39) .
Cycloheximide chase analysis. Rnf8 -/-Trp53 Δ/Δ mammary tumor cells reconstituted with empty vector (mock) or RNF8 were seeded onto 6-cm dishes overnight. Cells were then either left untreated or treated with 150 μM of cycloheximide for 0.5-6 hours, and immunoblot analysis was performed to determine levels of N1ICD, RNF8-FLAG, and β-actin. Bioinformatics. To characterize clinical relevance of RNF8 in human breast cancer, we used KM Plotter (http://kmplot.com) (19) , 2017 version, with data from 5,142 breast cancer samples, of which 3,955 had patient survival information, downloaded from GEO (Affymetrix microarrays only), the European Genome-Phenome Archive (EGA), and TCGA. We plotted relapse-free survival using the median expression level of RNF8 (probes 203160_s_at and 203161_s_at) to classify breast cancer cases as having either high or low RNF8 expression. The specificity of the 2 RNF8 probes available in the KM Plotter was analyzed using Ensembl (www.ensembl.org). Isoforms of RNF8 were inspected using Ensembl and UniProt (http://www.uniprot.org).
Statistics. Two-tailed unpaired Student's t test was used to compare 2 means. Multiple comparisons were performed using 1-way Medium was changed every 4 days to replenish drug levels. Cells were allowed to grow for 12-25 days, depending on the tumor cells, before their fixation with methanol and staining with crystal violet. Numbers of colonies in each dish were counted, and pictures of the dishes were taken. All experiments were performed in triplicate. Data from treated samples were normalized to their respective untreated controls. The investigators were blinded during the scoring of colonies.
Protein analysis and cytoplasmic and nuclear extract preparation. Immunoblot analyses were performed using standard protocols. For fractionation, 3 × 10 7 cells were washed with PBS and resuspended jci.org Volume 128 Number 10 October 2018
